133 related articles for article (PubMed ID: 18432364)
21. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders.
Federici AB; Rand JH; Mannucci PM
Hematol J; 2001; 2(6):358-62. PubMed ID: 11920274
[No Abstract] [Full Text] [Related]
22. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
23. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative syndromes and the associated risk of coronary artery disease.
Ganti AK; Potti A; Koka VK; Pervez H; Mehdi SA
Thromb Res; 2003 May; 110(2-3):83-6. PubMed ID: 12893021
[TBL] [Abstract][Full Text] [Related]
26. Presence of human herpesvirus 8 (HHV-8) DNA sequences in patients with lymphoproliferative diseases and chronic blood disorders.
Keyvani H; Karbalaie Niya MH; Esghaei M; Bokharaei-Salim F; Monavari SHR
Microb Pathog; 2017 Oct; 111():431-434. PubMed ID: 28916317
[TBL] [Abstract][Full Text] [Related]
27. Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.
Kennedy JA; Medeiros JJF; Dobson SM; Arruda A; Sukhai MA; Stockley T; Tierens A; Minden MD; Kamel-Reid S; Dick JE; Gupta V
Blood; 2018 Nov; 132(20):2201-2205. PubMed ID: 30249785
[No Abstract] [Full Text] [Related]
28. Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
Kessler CM; Klein HG; Havlik RJ
Br J Haematol; 1982 Jan; 50(1):157-67. PubMed ID: 6976793
[TBL] [Abstract][Full Text] [Related]
29. Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.
Ichinohasama R; Miura I; Takahashi N; Sugawara T; Tamate E; Endoh K; Endoh F; Naganuma H; DeCoteau JF; Griffin JD; Kadin ME; Ooya K
Leukemia; 2000 Jan; 14(1):169-82. PubMed ID: 10637493
[TBL] [Abstract][Full Text] [Related]
30. Association of breast cancer with myeloproliferative disorders.
Cornfield DB; Binder RA; Rath CE
South Med J; 1977 Jul; 70(7):780-3. PubMed ID: 195348
[TBL] [Abstract][Full Text] [Related]
31. Coexistence of sarcoidosis and malignant disease: causality or coincidence?
Brincker H
Sarcoidosis; 1989 Mar; 6(1):31-43. PubMed ID: 2657921
[TBL] [Abstract][Full Text] [Related]
32. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
33. [Vasculitis and malignant diseases].
Gran JT
Tidsskr Nor Laegeforen; 1997 Apr; 117(11):1627-9. PubMed ID: 9198948
[TBL] [Abstract][Full Text] [Related]
34. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
35. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloproliferative diseases.
de Lacerda JF; Oliveira SN; Ferro JM
Handb Clin Neurol; 2014; 120():1073-81. PubMed ID: 24365372
[TBL] [Abstract][Full Text] [Related]
37. Familial malignant blood disease in the country of Jämtland, Sweden.
Eriksson M; Bergström I
Eur J Haematol; 1987 Mar; 38(3):241-5. PubMed ID: 3595812
[TBL] [Abstract][Full Text] [Related]
38. [Circulating immune complexes in patients with lymphoproliferative and myeloproliferative diseases].
Loni C; Ricci S; Azzarà A; Bertoncini G
Quad Sclavo Diagn; 1984 Jun; 20(2):193-202. PubMed ID: 6441963
[TBL] [Abstract][Full Text] [Related]
39. Myeloproliferative neoplasms cause glomerulopathy.
Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B surface antigenaemia in patients with malignant lymphoproliferative disorders.
Olatunji PO; Okpala IE; Sorunmu MA
Tokai J Exp Clin Med; 1991 Oct; 16(3-4):171-3. PubMed ID: 1811350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
